A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma

UVA Tracking #
300014
Principal Investigator
Elizabeth M Gaughan
Contact
Contact Phone
Official Trial Title
A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab Compared with Pembrolizumab in Patients with Resectable Stage III and IV Melanoma
Study Description

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have a high-risk melanoma skin cancer, which is resectable (can be surgically removed). The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to pembrolizumab as peri-operative therapy in participants with high-risk melanoma.
You will be on active treatment for approximately 1 year. Once you have completed the treatment portion of the study, you will enter the follow-up period for up to 4 years after your first dose of study treatment.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/study/NCT06190951

uvacancertrials@hscmail.mcc.virginia.edu

The (department, division name) seeks (insert as applies: adults/men/women/adolescents/children) ages (insert) with (insert condition) for a research study. The purpose of the study is (insert purpose of study - eg.to test the effectiveness of an investigational medicine; or to find out how stress effects blood pressure.)

(Optional)You may be eligible for this study if: (insert brief eligibility criteria 3 or 4 top criteria and in lay language. Do not copy eligibility criteria from the protocol)

Study involves (insert procedures-examples: taking an experimental medicine/placebo, blood draws, x rays, overnight stays,) (Insert x number of visits every x (weeks, months,) each visit lasting x amount of time or give range).

Insert one of the following:
Study-related (insert exams, tests and experimental medication) provided at no cost.
or
Participant’s insurance company will be billed for medication, test,s and procedures

Compensation

No Compensation